Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 2:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 127 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 1000 mg acetaminophen Clear all
Recruiting Phase 3 Interventional

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

NCT06966700
View directory record Official record
Conditions
Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Interventions
Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Capecitabine, Olaparib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
63
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 5, 2026, 2:30 PM EDT
Completed Phase 4 Interventional Results available

Post-operative Dental Pain Study Comparing Analgesic Efficacy

NCT01082081
View directory record Official record
Conditions
Post-surgical Dental Pain
Interventions
Paracetamol 1000 mg, Paracetamol 500 mg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Austin, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 13, 2015 · Synced Oct 5, 2026, 2:30 PM EDT
Not yet recruiting Phase 4 Interventional

Suzetrigine Versus Standard Analgesia After Skin Cancer Surgery

NCT07843134
View directory record Official record
Conditions
Postoperative Pain, Acute Pain, Skin Cancer, Cutaneous Malignancy, Mohs Surgery
Interventions
Suzetrigine, Acetaminophen Plus Ibuprofen
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
3
States / cities
Maple Grove, Minnesota • Minneapolis, Minnesota • Wyoming, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 5, 2026, 2:30 PM EDT
Completed Phase 4 Interventional Results available

Preoperative IV Versus Oral Acetaminophen

NCT03468920
View directory record Official record
Conditions
Pain, Postoperative
Interventions
IV Acetaminophen, PO Acetaminophen, PO Placebo, IV Solution Placebo
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Oct 5, 2026, 2:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

NCT02431559
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Durvalumab, Pegylated Liposomal Doxorubicin, Motolimod
Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
4
States / cities
Phoenix, Arizona • New York, New York • Hilliard, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 5, 2026, 2:30 PM EDT
Completed Phase 4 Interventional Results available

Multimodal Pain Study in Free Flap Patients

NCT04246697
View directory record Official record
Conditions
Head and Neck Cancer, Analgesia
Interventions
Tylenol, Oxycodone, Morphine, Gabapentin, toradol, Bupivacaine
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 5, 2026, 2:30 PM EDT
Not yet recruiting Phase 4 Interventional

Examining Analgesic Synergy and Efficacy in Trauma Care

NCT07435077
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine, Oxycodone
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 5, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

A Dental Pain Study to Test the Effectiveness of a New Pain Reliever Medicine

NCT02209181
View directory record Official record
Conditions
Pain
Interventions
JNJ-10450232 / Not yet marketed, acetaminophen / Tylenol
Drug
Lead sponsor
McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Oct 5, 2026, 2:30 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Opioid-limiting Pain Management Protocol in Men Undergoing Urethroplasty

NCT03859024
View directory record Official record
Conditions
Pain, Postoperative, Urethral Stricture
Interventions
Oxycodone, Acetaminophen, Gabapentin, celebrex, Bupivacaine, Ibuprofen 800 mg, Dexamethasone
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 5, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

NCT04165096
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Pembrolizumab, Boserolimab, MK-4830, diphenhydramine, acetaminophen, MK-0482
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
18
States / cities
Gilbert, Arizona • Duarte, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 5, 2026, 2:30 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Pain Management Following Sinus Surgery

NCT03822962
View directory record Official record
Conditions
Nasal Sinus; Inflammation, Opioid Abuse, Pain, Postoperative
Interventions
Ibuprofen 600Mg Tablet, Standard Regimen | Tylenol
Drug · Other
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Omaha, Nebraska • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 5, 2026, 2:30 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus

NCT00137969
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Rituximab, Placebo, Prednisone, Acetaminophen, Diphenhydramine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
16 Years to 75 Years
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
63
States / cities
Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 5, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study

NCT01229449
View directory record Official record
Conditions
Post-operative Pain
Interventions
Ibuprofen/acetaminophen, Ibuprofen/acetaminophen (higher dose), Nurofen Plus®, Panadeine® Extra, Placebo
Drug
Lead sponsor
Reckitt Benckiser LLC
Industry
Eligibility
16 Years and older
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Oct 5, 2026, 2:30 PM EDT
Terminated Phase 2 Interventional Results available

BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance

NCT02029638
View directory record Official record
Conditions
Kidney Transplantation
Interventions
anti-thymocyte globulin, Fludarabine, Cyclophosphamide, Total Body Irradiation, acetaminophen, diphenhydramine, methylprednisolone, bone marrow transplant, MESNA, mycophenolate mofetil, prednisone, filgrastim
Biological · Drug · Radiation
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Oct 5, 2026, 2:30 PM EDT
Terminated Phase 2Phase 3 Interventional

Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy

NCT05597878
View directory record Official record
Conditions
Pain Management, Opioid Use, Prostate Cancer
Interventions
Oxycodone, Acetaminophen, Ketamine, Ketorolac
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 75 Years · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 5, 2026, 2:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Hydromorphone on Responses to Verbal Tasks

NCT02205983
View directory record Official record
Conditions
Healthy
Interventions
2 mg hydromorphone, 1000 mg Acetaminophen, 4 mg hydromorphone, dextrose
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 5, 2026, 2:30 PM EDT
Recruiting Phase 3 Interventional

Suzetrigine Frame Trial Comparing Suzetrigine and Acetaminophen

NCT07525219
View directory record Official record
Conditions
Analgesic Efficacy
Interventions
Suzetrigine, acetaminophen
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 5, 2026, 2:30 PM EDT
Terminated Phase 1 Interventional Results available

Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation

NCT02188719
View directory record Official record
Conditions
Liver Transplantation
Interventions
Anti-Thymocyte Globulin - Rabbit, darTreg Infusion, Everolimus, Tacrolimus, Mycophenolate mofetil, Prednisone, Acetaminophen, Diphenhydramine, Anti-Infective Prophylaxis, Leukapheresis, Blood draws, Liver biopsies, Liver transplantation
Biological · Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
21 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 5, 2026, 2:30 PM EDT
Completed Phase 1 Interventional

Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease

NCT02867800
View directory record Official record
Conditions
Sickle Cell Disease, Graft Versus Host Disease
Interventions
Diphenhydramine, Acetaminophen, Methylprednisolone, Meperidine, Alemtuzumab, Thymoglobulin, Fludarabine, Melphalan, Thiotepa, Cyclosporine, Tacrolimus, Methotrexate, Abatacept, Marrow infusion, Sirolimus, Mycophenolate Mofetil
Drug · Procedure
Lead sponsor
Monica Bhatia
Other
Eligibility
3 Years to 20 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 5, 2026, 2:30 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus

NCT00381810
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Rituximab, Methylprednisolone, Acetaminophen, Diphenhydramine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
16 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
11
States / cities
Paradise Valley, Arizona • San Leandro, California • Boise, Idaho + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 5, 2026, 2:30 PM EDT
Not listed Phase 4 Interventional

Randomized Trial of Narcotic vs Non-Narcotic Pain Modulation After Labrum Repair

NCT05974423
View directory record Official record
Conditions
Postoperative Pain, Acute, Opioid Use, Labral Tear, Glenoid
Interventions
Tylenol, Ibuprofen, and Oxycodone, Tylenol and Ibuprofen only
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
15 Years to 25 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 5, 2026, 2:30 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

NCT04963296
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Obinutuzumab, Placebo, Acetaminophen/Paracetamol, Diphenhydramine hydrochloride, Methylprednisolone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
14
States / cities
Anniston, Alabama • Searcy, Arkansas • Fullerton, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 5, 2026, 2:30 PM EDT
Completed Phase 2 Interventional

Study of Acetaminophen (ACE) in Post-operative Dental Pain

NCT02320708
View directory record Official record
Conditions
Dental Pain
Interventions
Acetaminophen (ACE) (1000 mg), Commercial ACE (1000 mg), Commercial Ibuprofen (IBU) (400 mg), Placebo
Drug
Lead sponsor
Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
Industry
Eligibility
17 Years to 50 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 5, 2026, 2:30 PM EDT
Not listed Phase 3 Interventional

Efficacy of Myalgesin™ to Support Joint Function in Patients With Knee Osteoarthritis

NCT00577330
View directory record Official record
Conditions
Osteoarthritis
Interventions
Myalgesin™ (celery seed extract, Boswellia serrata extract, Phellodendron extract)
Dietary Supplement
Lead sponsor
ProThera, Inc.
Industry
Eligibility
50 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 5, 2026, 2:30 PM EDT